Management of hypertension and heart failure in patients with Addison's disease
- PMID: 25138826
- DOI: 10.1111/cen.12592
Management of hypertension and heart failure in patients with Addison's disease
Abstract
Addison's disease may be complicated by hypertension and less commonly by heart failure. We review the pathophysiology of the renin-angiotensin-aldosterone axis in Addison's disease and how this is altered in the setting of hypertension and heart failure. An essential first step in management in both conditions is optimizing glucocorticoid replacement and considering dose reduction if excessive. Following this, if a patient with Addison's disease remains hypertensive, the fludrocortisone dose should be reviewed and reduced if there are clinical and/or biochemical signs of mineralocorticoid excess. In the absence of such signs, where the renin is towards the upper end of the normal range or elevated, an angiotensin II (AII) receptor antagonist or angiotensin converting enzyme (ACE) inhibitor is the treatment of choice, and the fludrocortisone dose should remain unchanged. Dihydropyridine calcium channel blockers are clinically useful as second line agents, but diuretics should be avoided. In the setting of heart failure, there is an increase in total body sodium and water; therefore, it is appropriate to reduce and rarely consider ceasing the fludrocortisone. Loop diuretics may be used, but not aldosterone antagonists such as spironolactone or eplerenone. Standard treatment with ACE inhibitors, or as an alternative, AII receptor antagonists, are appropriate. Measurements of renin are no longer helpful in heart failure to determine the volume status but plasma levels of brain natriuretic peptide (BNP/proBNP) may help guide therapy.
© 2014 John Wiley & Sons Ltd.
Similar articles
-
Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease.J Clin Endocrinol Metab. 1996 Apr;81(4):1411-5. doi: 10.1210/jcem.81.4.8636343. J Clin Endocrinol Metab. 1996. PMID: 8636343 Clinical Trial.
-
Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.Circ Heart Fail. 2014 Jan;7(1):131-9. doi: 10.1161/CIRCHEARTFAILURE.113.000527. Epub 2013 Dec 18. Circ Heart Fail. 2014. PMID: 24352403 Clinical Trial.
-
Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.Circ Heart Fail. 2008 May;1(1):17-24. doi: 10.1161/CIRCHEARTFAILURE.107.740704. Circ Heart Fail. 2008. PMID: 19808266 Clinical Trial.
-
The renin-angiotensin-aldosterone system and heart failure.Cardiol Clin. 2014 Feb;32(1):21-32, vii. doi: 10.1016/j.ccl.2013.09.002. Cardiol Clin. 2014. PMID: 24286576 Review.
-
Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.Fiziol Cheloveka. 2005 Nov-Dec;31(6):97-105. Fiziol Cheloveka. 2005. PMID: 16366159 Review.
Cited by
-
Plasma renin levels are associated with cardiac function in primary adrenal insufficiency.Endocrine. 2019 Aug;65(2):399-407. doi: 10.1007/s12020-019-01974-1. Epub 2019 Jun 8. Endocrine. 2019. PMID: 31177424 Free PMC article.
-
Endothelial CHOP as a central mechanism in renovascular hypertension-induced vascular endothelial dysfunction and cardiac fibrosis.Cell Mol Life Sci. 2025 Jun 13;82(1):232. doi: 10.1007/s00018-025-05741-6. Cell Mol Life Sci. 2025. PMID: 40512182 Free PMC article.
-
Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab. 2016 Feb;101(2):364-89. doi: 10.1210/jc.2015-1710. Epub 2016 Jan 13. J Clin Endocrinol Metab. 2016. PMID: 26760044 Free PMC article. Review.
-
Role of plasmacytoid dendritic cells in vascular dysfunction in mice with renovascular hypertension.Heliyon. 2024 May 29;10(11):e31799. doi: 10.1016/j.heliyon.2024.e31799. eCollection 2024 Jun 15. Heliyon. 2024. PMID: 38882290 Free PMC article.
-
A Contemporary Approach to the Diagnosis and Management of Adrenal Insufficiency.Endocrinol Metab (Seoul). 2024 Feb;39(1):73-82. doi: 10.3803/EnM.2024.1894. Epub 2024 Jan 22. Endocrinol Metab (Seoul). 2024. PMID: 38253474 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous